Literature DB >> 22275107

Incidence and demography of femur fractures with and without atypical features.

Adrianne C Feldstein1, Dennis Black, Nancy Perrin, A Gabriela Rosales, Darin Friess, David Boardman, Richard Dell, Arthur Santora, Julie M Chandler, Mary M Rix, Eric Orwoll.   

Abstract

The case definition, community incidence, and characteristics of atypical femoral shaft fractures (FSFs) are poorly understood. This retrospective study utilized electronic medical records and radiograph review among women ≥50 years of age and men ≥65 years of age from January 1996 to June 2009 at Kaiser Permanente Northwest to describe the incidence rates and characteristics of subgroups of femur fractures. Fractures were categorized based on the American Society for Bone and Mineral Research (ASBMR) as atypical fracture major features (AFMs) (low force, shaft location, transverse or short oblique, noncomminuted) and AFMs with additional minor radiograph features (AFMms) (beaking, cortical thickening, or stress fracture). There were 5034 fractures in the study. The incidence rates of FSFs (without atypical features) and AFMs appeared flat (cumulative incidence: 18.2 per 100,000 person-years, 95% CI = 16.0-20.7; 5.9 per 100,000 person-years, 95% CI = 4.6-7.4; respectively) with 1,271,575 person-years observed. The proportion of AFMs that were AFMms increased over time. Thirty percent of AFMs had any dispensing of a bisphosphonate prior to the fracture, compared to 15.8% of the non-atypical FSFs. Years of oral glucocorticosteroid dispensing appeared highest in AFM and AFMm fractures. Those with AFMs only were older and had a lower frequency of bisphosphonate dispensing compared to those with AFMms. We conclude that rates of FSFs, with and without atypia, were low and stable over 13.5 years. Patients with only AFMs appear to be different from those with AFMms; it may be that only the latter group is atypical. There appear to be multiple associated risk factors for AFMm fractures.
Copyright © 2012 American Society for Bone and Mineral Research.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22275107     DOI: 10.1002/jbmr.1550

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  52 in total

1.  Atypical femur fractures: a survey of current practices in orthopedic surgery.

Authors:  P S Schneider; M Wall; J P Brown; A M Cheung; E J Harvey; S N Morin
Journal:  Osteoporos Int       Date:  2017-08-02       Impact factor: 4.507

Review 2.  Atypical femoral fractures: epidemiology, etiology, and patient management.

Authors:  Eve Donnelly; Anas Saleh; Aasis Unnanuntana; Joseph M Lane
Journal:  Curr Opin Support Palliat Care       Date:  2012-09       Impact factor: 2.302

3.  High and pointed type of femoral localized reaction frequently extends to complete and incomplete atypical femoral fracture in patients with autoimmune diseases on long-term glucocorticoids and bisphosphonates.

Authors:  H Sato; N Kondo; T Nakatsue; Y Wada; J Fujisawa; J J Kazama; T Kuroda; Y Suzuki; M Nakano; N Endo; I Narita
Journal:  Osteoporos Int       Date:  2017-04-13       Impact factor: 4.507

4.  Radiological criteria for atypical features of femur fractures: what we can learn when applied in a clinical study setting.

Authors:  E S LeBlanc; A G Rosales; H K Genant; R M Dell; D M Friess; D L Boardman; A C Santora; D C Bauer; A E de Papp; D M Black; E S Orwoll
Journal:  Osteoporos Int       Date:  2019-02-26       Impact factor: 4.507

5.  Are atypical femur fractures linked with oral bisphosphonate use?

Authors: 
Journal:  Bonekey Rep       Date:  2012-04-04

6.  Lateral Femoral Bowing and the Location of Atypical Femoral Fractures.

Authors:  Hyunseung Yoo; Youngho Cho; Youngbo Park; Sungsoo Ha
Journal:  Hip Pelvis       Date:  2017-06-02

Review 7.  Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: sensitivity and trim and fill studies.

Authors:  Jie Liu; Hong-xin Zhang; Xiong-xiong Lu; Jia-jia Hu; Lian-fu Deng
Journal:  Genet Test Mol Biomarkers       Date:  2013-11-08

Review 8.  Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: a systematic review and meta-analysis.

Authors:  Lydia Gedmintas; Daniel H Solomon; Seoyoung C Kim
Journal:  J Bone Miner Res       Date:  2013-08       Impact factor: 6.741

9.  The cumulative incidence of and risk factors for latent beaking in patients with autoimmune diseases taking long-term glucocorticoids and bisphosphonates.

Authors:  H Sato; N Kondo; Y Wada; T Nakatsue; S Iguchi; J Fujisawa; J J Kazama; T Kuroda; M Nakano; N Endo; I Narita
Journal:  Osteoporos Int       Date:  2015-10-30       Impact factor: 4.507

Review 10.  Bisphosphonates and nonhealing femoral fractures: analysis of the FDA Adverse Event Reporting System (FAERS) and international safety efforts: a systematic review from the Research on Adverse Drug Events And Reports (RADAR) project.

Authors:  Beatrice J Edwards; Andrew D Bunta; Joseph Lane; Clarita Odvina; D Sudhaker Rao; Dennis W Raisch; June M McKoy; Imran Omar; Steven M Belknap; Vishvas Garg; Allison J Hahr; Athena T Samaras; Matthew J Fisher; Dennis P West; Craig B Langman; Paula H Stern
Journal:  J Bone Joint Surg Am       Date:  2013-02-20       Impact factor: 5.284

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.